Literature DB >> 20338216

Protection of chickens, with or without maternal antibodies, against IBDV infection by a recombinant IBDV-VP2 protein.

Xuemei Zhou1, Decheng Wang, Jinmao Xiong, Peijun Zhang, Yongqing Li, Ruiping She.   

Abstract

The use of avian herpesviruses (Marek's disease virus, MDV) as vectors to express the capsid protein of infectious bursal disease virus (IBDV) was well established, and its protection against IBDV challenge has been evaluated previously. However, there is little data about rMDV1 expressing the VP2 protein of IBDV protecting SPF and commercial chickens against virulent IBDV (vIBDV) challenge. In this study, we constructed a stable rMDV1 expressing the VP2 protein of IBDV by inserting the coding sequence within the US10 gene of MDVl by homologous recombination and designated this as rMDVl-US10L, and evaluated effectiveness of the recombinant VP2 protein with SPF chickens and commercial chickens with maternal antibodies in vIBDV challenge. The results can be summarized as follows: (1) We constructed a rMDV1 expressing IBDV-VP2 under the control of the MDV1 glycoprotein B (gB) promoter [rMDV1-US10L]. (2) rMDV-VP2 protein was readily expressed and induced 53% protection against a vIBDV challenge in SPF chickens with 10(3)PFU/chicken, whereas 10(4)PFU induced 73% protection. (3) Vaccination of commercial chickens having maternal antibodies to rMDV1-VP2 induced 87% protection in vIBDV challenge, which was similar to results using the live vaccine, BJ87 IBDV strain, in commercial chickens. These results demonstrate that the VP2 antigen expressed in the MDV vector was an effective and stable vaccine in correlation with the vaccine efficacy against lethal IBDV challenge, and can provide a better protective effect that is likely to persist for the life of the chickens. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20338216     DOI: 10.1016/j.vaccine.2010.03.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit.

Authors:  Marina Arnold; Vijay Durairaj; Egbert Mundt; Katja Schulze; Karin D Breunig; Sven-Erik Behrens
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

Review 2.  Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies.

Authors:  Stefan Niewiesk
Journal:  Front Immunol       Date:  2014-09-16       Impact factor: 7.561

3.  Recombinant Marek's disease virus type 1 provides full protection against very virulent Marek's and infectious bursal disease viruses in chickens.

Authors:  Kai Li; Yongzhen Liu; Changjun Liu; Li Gao; Yanping Zhang; Hongyu Cui; Yulong Gao; Xiaole Qi; Li Zhong; Xiaomei Wang
Journal:  Sci Rep       Date:  2016-12-16       Impact factor: 4.379

4.  Gallid herpesvirus 3 SB-1 strain as a recombinant viral vector for poultry vaccination.

Authors:  Yashar Sadigh; Claire Powers; Simon Spiro; Miriam Pedrera; Andrew Broadbent; Venugopal Nair
Journal:  NPJ Vaccines       Date:  2018-05-28       Impact factor: 7.344

5.  Comparison of two attenuated infectious bursal disease vaccine strains focused on safety and antibody response in commercial broilers.

Authors:  Thotsapol Thomrongsuwannakij; Nataya Charoenvisal; Niwat Chansiripornchai
Journal:  Vet World       Date:  2021-01-11

6.  Avirulent Marek's disease virus type 1 strain 814 vectored vaccine expressing avian influenza (AI) virus H5 haemagglutinin induced better protection than turkey herpesvirus vectored AI vaccine.

Authors:  Hongyu Cui; Hongbo Gao; Xianlan Cui; Yan Zhao; Xingming Shi; Qiaoling Li; Shuai Yan; Ming Gao; Mei Wang; Changjun Liu; Yunfeng Wang
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

7.  HSC70 is required for infectious bursal disease virus (IBDV) infection in DF-1 cells.

Authors:  Chunbo Chen; Ying Qin; Kun Qian; Hongxia Shao; Jianqiang Ye; Aijian Qin
Journal:  Virol J       Date:  2020-05-06       Impact factor: 4.099

8.  Maternal antibody interference contributes to reduced rotavirus vaccine efficacy in developing countries.

Authors:  Claire E Otero; Stephanie N Langel; Maria Blasi; Sallie R Permar
Journal:  PLoS Pathog       Date:  2020-11-19       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.